These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma. Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942 [TBL] [Abstract][Full Text] [Related]
48. BMP4 Signaling Is Able to Induce an Epithelial-Mesenchymal Transition-Like Phenotype in Barrett's Esophagus and Esophageal Adenocarcinoma through Induction of SNAIL2. Kestens C; Siersema PD; Offerhaus GJ; van Baal JW PLoS One; 2016; 11(5):e0155754. PubMed ID: 27191723 [TBL] [Abstract][Full Text] [Related]
49. Malignant progression in Barrett's esophagus: pathology and molecular biology. Mueller J; Werner M; Siewert JR Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236 [TBL] [Abstract][Full Text] [Related]
50. Recurrent columnar-lined esophageal segments--study of the phenotypic characteristics using intestinal markers. Chaves P; Pereira AD; Cruz C; Suspiro A; Mendes de Almeida JC; Leitão CN; Soares J Dis Esophagus; 2002; 15(4):282-6. PubMed ID: 12472472 [TBL] [Abstract][Full Text] [Related]
51. Molecular biology of Barrett's cancer. Atherfold PA; Jankowski JA Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163 [TBL] [Abstract][Full Text] [Related]
52. Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. Arcidiacono D; Antonello A; Fassan M; Nucci D; Morbin T; Agostini M; Nitti D; Rugge M; Alberti A; Battaglia G; Realdon S Dig Liver Dis; 2017 Jun; 49(6):630-638. PubMed ID: 28185837 [TBL] [Abstract][Full Text] [Related]
53. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma. Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440 [TBL] [Abstract][Full Text] [Related]
54. [Pathogenesis of Barrett's esophagus--new findings in the experimental studies of duodenal reflux models]. Hattori T; Mukaisho K; Miwa K Nihon Rinsho; 2005 Aug; 63(8):1341-9. PubMed ID: 16101219 [TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068 [TBL] [Abstract][Full Text] [Related]
56. Surgical options and outcomes in Barrett's esophagus. Zaninotto G; Rizzetto C Curr Opin Gastroenterol; 2007 Jul; 23(4):452-5. PubMed ID: 17545785 [TBL] [Abstract][Full Text] [Related]
57. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. Kalatskaya I Ann N Y Acad Sci; 2016 Oct; 1381(1):74-91. PubMed ID: 27415609 [TBL] [Abstract][Full Text] [Related]